Heat Biologics Tightens Belt To Reach Late-2016 Inflection Points
This article was originally published in The Pink Sheet Daily
Biotech striving to hold on financially until it can deliver top-line data for bladder and lung cancer immunotherapy candidates, but then it will have to content with Roche entering the bladder cancer market with its PD-L1 inhibitor.
You may also be interested in...
How To Catch The Next Wave Of Cancer Immunotherapy
Forging a development partnership with a big pharma PD-1/L1 sponsor has become a sort of beauty contest with many in the running, and small companies are best advised to invest in good preclinical datasets to make the grade, execs say at the BIO Investor Forum in San Francisco.
PD-1 Progress May Shorten The Life Of Other Drugs
With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?
From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs
Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.